Company intelligence / Profile preview

Orinove Inc.

Thousand Oaks, California, USAorinoveinc.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ORIN1001 has completed Phase 1 dose escalation trials in the US and China, demonstrated early clinical activity as a single agent and in combination with standard of care in advanced solid tumors. Best response was observed in one subject treated over 41 months with multiple responders with late stage solid tumors. Currently in Phase 1b for IPF and poised to start Phase 2 for advanced solid tumors and metastatic breast cancer.

Therapeutic areas: OncologyPulmonologyNeurologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ORIN1001

Phase 2

Indications: Advanced solid tumors, Metastatic breast cancer, Idiopathic pulmonary fibrosis

2 more assets in the full pipeline.

Partnerships

Seeking strategic partners for ongoing development of ORIN1001

Beyond the preview

Go deeper on Orinove Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orinove Inc..